{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:58:03Z","timestamp":1791331083593,"version":"4.3.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T00:00:00Z","timestamp":1397347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11060-014-1433-2","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T02:47:13Z","timestamp":1397270833000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial"],"prefix":"10.1007","volume":"118","author":[{"given":"Wenyin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaacov Richard","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Werner-Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Judy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Moshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voichita","family":"Bar-Ad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,13]]},"reference":[{"key":"1433_CR1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.seminoncol.2007.12.003","volume":"35","author":"DW Andrews","year":"2008","unstructured":"Andrews DW (2008) Current neurosurgical management of brain metastases. Semin Oncol 35:100\u2013107","journal-title":"Semin Oncol"},{"key":"1433_CR2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Auperin","year":"1999","unstructured":"Auperin A et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341:476\u2013484","journal-title":"N Engl J Med"},{"key":"1433_CR3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-09-0038","volume":"8","author":"A Baschnagel","year":"2009","unstructured":"Baschnagel A et al (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8:1589\u20131595","journal-title":"Mol Cancer Ther"},{"key":"1433_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1748-717X-6-33","volume":"6","author":"A Bratland","year":"2011","unstructured":"Bratland A et al (2011) Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat Oncol 6:33","journal-title":"Radiat Oncol"},{"key":"1433_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","volume":"114","author":"K Camphausen","year":"2005","unstructured":"Camphausen K et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380\u2013386","journal-title":"Int J Cancer"},{"key":"1433_CR6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0070-2153(05)73006-4","volume":"73","author":"D Cerna","year":"2006","unstructured":"Cerna D, Camphausen K, Tofilon PJ (2006) Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 73:173\u2013204","journal-title":"Curr Top Dev Biol"},{"key":"1433_CR7","first-page":"54","volume":"5","author":"JE Chang","year":"2007","unstructured":"Chang JE, Robins HI, Mehta MP (2007) Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 5:54\u201364","journal-title":"Clin Adv Hematol Oncol"},{"key":"1433_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/neuonc\/nor187","volume":"14","author":"P Chinnaiyan","year":"2012","unstructured":"Chinnaiyan P et al (2012) Phase i trial of vorinostat combined with bevacizumab and cpt-11 in recurrent glioblastoma. Neuro Oncol 14:93\u2013100","journal-title":"Neuro Oncol"},{"key":"1433_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","volume":"62","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan P et al (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223\u2013229","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1433_CR10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/MPA.0b013e3181dd63e1","volume":"39","author":"A Deorukhkar","year":"2010","unstructured":"Deorukhkar A et al (2010) Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 39:1277\u20131283","journal-title":"Pancreas"},{"key":"1433_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous t-cell lymphoma (ctcl). Blood 109:31\u201339","journal-title":"Blood"},{"key":"1433_CR12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-011-1762-1","volume":"69","author":"MG Fakih","year":"2012","unstructured":"Fakih MG et al (2012) A randomized phase ii study of two doses of vorinostat in combination with 5-fu\/lv in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 69:743\u2013751","journal-title":"Cancer Chemother Pharmacol"},{"key":"1433_CR13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","volume":"14","author":"BB Friday","year":"2012","unstructured":"Friday BB et al (2012) Phase ii trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14:215\u2013221","journal-title":"Neuro Oncol"},{"key":"1433_CR14","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis E et al (2009) Phase ii trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052\u20132058","journal-title":"J Clin Oncol"},{"key":"1433_CR15","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis E et al (2009) Phase ii trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27:2052\u20132058","journal-title":"J Clin Oncol"},{"key":"1433_CR16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","volume":"17","author":"P Gallinari","year":"2007","unstructured":"Gallinari P et al (2007) Hdacs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17:195\u2013211","journal-title":"Cell Res"},{"key":"1433_CR17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L et al (1997) Recursive partitioning analysis (rpa) of prognostic factors in three radiation therapy oncology group (rtog) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1433_CR18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly E et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of huntington\u2019s disease. Proc Natl Acad Sci USA 100:2041\u20132046","journal-title":"Proc Natl Acad Sci USA"},{"key":"1433_CR19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1471-4159.2005.03098.x","volume":"93","author":"YE Ilker","year":"2005","unstructured":"Ilker YE et al (2005) Suberoylanilide hydroxamic acid (saha) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93:992\u2013999","journal-title":"J Neurochem"},{"key":"1433_CR20","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1038\/sj.onc.1209417","volume":"25","author":"TC Karagiannis","year":"2006","unstructured":"Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:3885\u20133893","journal-title":"Oncogene"},{"key":"1433_CR21","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291\u20137300","journal-title":"Cancer Res"},{"key":"1433_CR22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"MS Kim","year":"2001","unstructured":"Kim MS et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7:437\u2013443","journal-title":"Nat Med"},{"key":"1433_CR23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev 1:194\u2013202","journal-title":"Nat Rev"},{"key":"1433_CR24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","volume":"91","author":"PA Marks","year":"2004","unstructured":"Marks PA et al (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137\u2013168","journal-title":"Adv Cancer Res"},{"key":"1433_CR25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","volume":"306","author":"S Mueller","year":"2011","unstructured":"Mueller S et al (2011) Cooperation of the hdac inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 306:223\u2013229","journal-title":"Cancer Lett"},{"key":"1433_CR26","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","volume":"11","author":"A Munshi","year":"2005","unstructured":"Munshi A et al (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912\u20134922","journal-title":"Clin Cancer Res"},{"key":"1433_CR27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","volume":"5","author":"A Munshi","year":"2006","unstructured":"Munshi A et al (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-h2ax foci. Mol Cancer Ther 5:1967\u20131974","journal-title":"Mol Cancer Ther"},{"key":"1433_CR28","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","volume":"15","author":"D Palmieri","year":"2009","unstructured":"Palmieri D et al (2009) Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15:6148\u20136157","journal-title":"Clin Cancer Res"},{"key":"1433_CR29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","volume":"280","author":"RA Patchell","year":"1998","unstructured":"Patchell RA et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485\u20131489","journal-title":"JAMA"},{"key":"1433_CR30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494\u2013500","journal-title":"N Engl J Med"},{"key":"1433_CR31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-011-0204-x","volume":"14","author":"DM Peereboom","year":"2012","unstructured":"Peereboom DM (2012) Clinical trial design in brain metastasis: approaches for a unique patient population. Curr Oncol Rep 14:91\u201396","journal-title":"Curr Oncol Rep"},{"key":"1433_CR32","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2010.30.2307","volume":"28","author":"SS Ramalingam","year":"2010","unstructured":"Ramalingam SS et al (2010) Phase i study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol 28:4507\u20134512","journal-title":"J Clin Oncol"},{"key":"1433_CR33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10549-011-1928-x","volume":"132","author":"B Ramaswamy","year":"2012","unstructured":"Ramaswamy B et al (2012) Phase i\u2013ii study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and hsp90 inhibition in vivo. Breast Cancer Res Treat 132:1063\u20131072","journal-title":"Breast Cancer Res Treat"},{"key":"1433_CR34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","volume":"11","author":"AH Ree","year":"2010","unstructured":"Ree AH et al (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (pravo) phase 1 study. Lancet Oncol 11:459\u2013464","journal-title":"Lancet Oncol"},{"key":"1433_CR35","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95:S2\u2013S6","journal-title":"Br J Cancer"},{"key":"1433_CR36","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","volume":"95","author":"VM Richon","year":"1998","unstructured":"Richon VM et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003\u20133007","journal-title":"Proc Natl Acad Sci USA"},{"key":"1433_CR37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10637-010-9503-6","volume":"30","author":"BJ Schneider","year":"2012","unstructured":"Schneider BJ et al (2012) Phase i study of vorinostat (suberoylanilide hydroxamic acid, nsc 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 30:249\u2013257","journal-title":"Invest New Drugs"},{"key":"1433_CR38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","volume":"70","author":"PW Sperduto","year":"2008","unstructured":"Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the rtog database. Int J Radiat Oncol Biol Phys 70:510\u2013514","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1433_CR39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","volume":"17","author":"A Stathis","year":"2011","unstructured":"Stathis A et al (2011) Phase i study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin\u2019s lymphomas. Clin Cancer Res 17:1582\u20131590","journal-title":"Clin Cancer Res"},{"key":"1433_CR40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMct0806951","volume":"362","author":"JH Suh","year":"2010","unstructured":"Suh JH (2010) Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 362:1119\u20131127","journal-title":"N Engl J Med"},{"key":"1433_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-007-9337-z","volume":"83","author":"HC Ugur","year":"2007","unstructured":"Ugur HC et al (2007) Continuous intracranial administration of suberoylanilide hydroxamic acid (saha) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83:267\u2013275","journal-title":"J Neurooncol"},{"key":"1433_CR42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","volume":"13","author":"D Yin","year":"2007","unstructured":"Yin D et al (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13:1045\u20131052","journal-title":"Clin Cancer Res"},{"key":"1433_CR43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1667\/RR3192","volume":"161","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Jung M, Dritschilo A (2004) Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161:667\u2013674","journal-title":"Radiat Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-014-1433-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-014-1433-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:54:52Z","timestamp":1565340892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-014-1433-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,13]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s11060-014-1433-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,13]]}}}